{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:33:03Z","timestamp":1781641983903,"version":"3.54.5"},"reference-count":57,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["R34AA029447"],"award-info":[{"award-number":["R34AA029447"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Substance Abuse"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:p>While there is limited research in the field regarding the various dimensions of co-use of alcohol and opioid medication, particularly related to co-use and levels of severity, our research has shown 20% to 30% of community pharmacy patients receiving opioid pain medications are engaged in co-use. Co-use of alcohol and opioid medications is a significant risk factor for opioid-related overdose. Community pharmacy is a valuable yet underutilized resource and setting for addressing the US opioid epidemic, with an untapped potential for identification of and intervention for risks associated with co-use of alcohol and opioids. This commentary describing the \u201cCo-use of Opioid Medications and Alcohol Prevention Study (COAPS)\u201d offers an innovative and promising approach to mitigating serious risks associated with co-use of alcohol (risk and non-risk use) and opioids in community pharmacy. COAPS aim 1involves adapting an existing opioid misuse intervention to target co-use of alcohol and opioid mediations. COAPS aim 2 involves testing the adapted intervention within a small-scale pilot randomized controlled trial (N\u2009=\u200940) to examine feasibility, acceptability and preliminary efficacy of the intervention versus standard care. COAPS aim 3 involves conducting key informant interviews related to future implementation of larger scale studies or service delivery in community pharmacy settings.<\/jats:p>","DOI":"10.1177\/08897077231191840","type":"journal-article","created":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T06:33:40Z","timestamp":1695191620000},"page":"130-135","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Co-use of Opioid Medications and Alcohol Prevention Study (COAPS)"],"prefix":"10.1177","volume":"44","author":[{"given":"Alina","family":"Cernasev","sequence":"first","affiliation":[{"name":"University of Tennessee Health Sciences Center, Nashville, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Hohmeier","sequence":"additional","affiliation":[{"name":"University of Tennessee Health Sciences Center, Nashville, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Field","sequence":"additional","affiliation":[{"name":"Department of Psychology, University of Texas, El Paso, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2453-8871","authenticated-orcid":false,"given":"Adam J.","family":"Gordon","sequence":"additional","affiliation":[{"name":"Division of Epidemiology, University of Utah, Salt Lake City, UT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy","family":"Elliott","sequence":"additional","affiliation":[{"name":"University of Tennessee Health Sciences Center, Nashville, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2297-9702","authenticated-orcid":false,"given":"Kristi","family":"Carlston","sequence":"additional","affiliation":[{"name":"Division of Epidemiology, University of Utah, Salt Lake City, UT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Broussard","sequence":"additional","affiliation":[{"name":"Division of Epidemiology, University of Utah, Salt Lake City, UT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0153-0252","authenticated-orcid":false,"given":"Gerald","family":"Cochran","sequence":"additional","affiliation":[{"name":"Division of Epidemiology, University of Utah, Salt Lake City, UT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,9,20]]},"reference":[{"key":"bibr1-08897077231191840","volume-title":"Medicine Use and Spending in the U.S. A Review of 2017 and Outlook to 2022","author":"IQVIA Institute","year":"2018"},{"key":"bibr2-08897077231191840","unstructured":"CDC. U.S. opioid prescribing rate maps. Centers for Disease Control. Published 2020. Accessed July 9, 2020. https:\/\/www.cdc.gov\/drugoverdose\/rxrate-maps\/index.html"},{"key":"bibr3-08897077231191840","unstructured":"NIDA. NIDA in the news. Published n.d. Accessed September 3, 2020. https:\/\/www.drugabuse.gov\/news-events\/nida-in-news"},{"key":"bibr4-08897077231191840","volume-title":"Overdose Deaths Declined But Remained Near Record Levels During the First Nine Months of 2022 as States Cope With Synthetic Opioids","author":"Common Wealth Fund","year":"2023"},{"key":"bibr5-08897077231191840","unstructured":"Kaiser Family Foundation. Opioid overdose deaths by type of opioid. Published 2023. Accessed June 2, 2023. https:\/\/www.kff.org\/other\/state-indicator\/opioid-overdose-deaths-by-type-of-opioid\/?currentTimeframe=0&sortModel=%7B%22colId%22:%22Synthetic%20Opioids,%20other%20than%20Methadone%20(e.g.%20fentanyl,%20tramadol)%22,%22sort%22:%22desc%22%7D"},{"key":"bibr6-08897077231191840","doi-asserted-by":"publisher","DOI":"10.1016\/S0278-5846(99)00060-3"},{"key":"bibr7-08897077231191840","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2012.04.017"},{"key":"bibr8-08897077231191840","doi-asserted-by":"publisher","DOI":"10.1080\/10550880802122620"},{"key":"bibr9-08897077231191840","doi-asserted-by":"publisher","DOI":"10.1016\/j.cger.2014.04.008"},{"key":"bibr10-08897077231191840","volume-title":"Highlights of Prescribing Information: Oxycodone","author":"FDA","year":"2018"},{"key":"bibr11-08897077231191840","volume-title":"Highlights of Prescribing Information: Percocet","author":"FDA","year":"2018"},{"key":"bibr12-08897077231191840","volume-title":"Highlights of Prescribing Information: Oxycontin","author":"FDA","year":"2018"},{"key":"bibr13-08897077231191840","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2021.108713"},{"key":"bibr14-08897077231191840","unstructured":"CDC. Drug overdose deaths in the United States hit record numbers in 2014. Published 2016. Accessed September 7, 2016. http:\/\/www.cdc.gov\/drugoverdose\/epidemic\/index.html"},{"key":"bibr15-08897077231191840","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0000000000000676"},{"key":"bibr16-08897077231191840","volume-title":"FDA Warns About Serious Risks and Death When Combining Opioid Pain or Cough Medicines With Benzodiazepines; Requires Its Strongest Warning","author":"FDA","year":"2016"},{"key":"bibr17-08897077231191840","volume-title":"Alcohol Screening and Brief Intervention for People Who Consume Alcohol and Use Opioids","author":"CDC","year":"2018"},{"key":"bibr18-08897077231191840","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2010.05.008"},{"key":"bibr19-08897077231191840","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2017.03.006"},{"key":"bibr20-08897077231191840","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2011.02.003"},{"key":"bibr21-08897077231191840","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2019.02.025"},{"key":"bibr22-08897077231191840","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2019.107570"},{"key":"bibr23-08897077231191840","volume":"56","author":"Cochran G","year":"2016","journal-title":"JAPhA"},{"key":"bibr24-08897077231191840","doi-asserted-by":"publisher","DOI":"10.7326\/M16-0317"},{"key":"bibr25-08897077231191840","volume-title":"Key Substance Use and Mental Health Indicators in the United States: Results From the 2019 National Survey on Drug Use and Health (HHS Publication No. SMA 18-5068, NSDUH Series H-53)","author":"SAMHSA","year":"2020"},{"issue":"12","key":"bibr26-08897077231191840","volume":"10","author":"Reith TP.","year":"2018","journal-title":"Cureus"},{"key":"bibr27-08897077231191840","volume-title":"Accreditation Standards and Key Elements for the Professional Program in Pharmacy Leading to the Doctor of Pharmacy Degree","author":"Accreditation Council for Pharmacy Education","year":"2015"},{"key":"bibr28-08897077231191840","volume-title":"Pharmacist-Provided Medication Therapy Management in Medicaid","author":"CDC","year":"2021"},{"key":"bibr29-08897077231191840","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.19271"},{"issue":"9","key":"bibr30-08897077231191840","first-page":"1057","volume":"15","author":"Presley B","year":"2019","journal-title":"RSAP"},{"issue":"9","key":"bibr31-08897077231191840","first-page":"1155","volume":"16","author":"Newman TV","year":"2020","journal-title":"RSAP"},{"key":"bibr32-08897077231191840","unstructured":"NIDA. Validation of a community pharmacy-based prescription drug monitoring program risk screening tool (PHARMSCREEN) (NIH HEAL Initiative). Published 2020. Accessed May 12, 2020. https:\/\/www.drugabuse.gov\/about-nida\/organization\/cctn\/ctn\/research-studies\/validation-community-pharmacy-based-prescription-drug-monitoring-program-risk-screening-tool"},{"key":"bibr33-08897077231191840","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2006.00255.x"},{"key":"bibr34-08897077231191840","doi-asserted-by":"publisher","DOI":"10.1177\/002204261104100207"},{"key":"bibr35-08897077231191840","volume-title":"Select Features of State Pharmacist Collaborative Practice Laws","author":"CDC","year":"2013"},{"key":"bibr36-08897077231191840","doi-asserted-by":"publisher","DOI":"10.1111\/j.1465-3362.2010.00234.x"},{"key":"bibr37-08897077231191840","unstructured":"Riffkin R. Americans rate nurses highest on honesty, ethical standards. Gallup. Published 2014. Accessed May 17, 2016. http:\/\/www.webcitation.org\/6hZbvKPDQ"},{"issue":"6","key":"bibr38-08897077231191840","first-page":"762","volume":"47","author":"Peacock G","year":"2007","journal-title":"JAPhA"},{"issue":"6","key":"bibr39-08897077231191840","volume":"62","author":"Grabenstein JD.","year":"2022","journal-title":"JAPhA"},{"key":"bibr40-08897077231191840","doi-asserted-by":"publisher","DOI":"10.3109\/15360288.2015.1101641"},{"issue":"2","key":"bibr41-08897077231191840","first-page":"293","volume":"12","author":"Cochran G","year":"2016","journal-title":"RSAP"},{"key":"bibr42-08897077231191840","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000148"},{"key":"bibr43-08897077231191840","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-011473"},{"key":"bibr44-08897077231191840","doi-asserted-by":"publisher","DOI":"10.1006\/pmed.1999.0467"},{"key":"bibr45-08897077231191840","doi-asserted-by":"publisher","DOI":"10.1111\/add.15613"},{"key":"bibr46-08897077231191840","doi-asserted-by":"publisher","DOI":"10.1111\/add.13263"},{"key":"bibr47-08897077231191840","volume":"47","author":"Wingood GM","year":"2008","journal-title":"JAIDS"},{"key":"bibr48-08897077231191840","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2016.22.1.81"},{"key":"bibr49-08897077231191840","doi-asserted-by":"publisher","DOI":"10.3402\/meo.v18i0.21747"},{"key":"bibr50-08897077231191840","doi-asserted-by":"publisher","DOI":"10.1016\/S0005-7894(05)80307-7"},{"key":"bibr51-08897077231191840","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4612-0357-5_3"},{"key":"bibr52-08897077231191840","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.158.16.1789"},{"key":"bibr53-08897077231191840","doi-asserted-by":"publisher","DOI":"10.1186\/1748-5908-4-50"},{"key":"bibr54-08897077231191840","unstructured":"CFIR.org. The consolidated framework for implementation research. Published 2020. Accessed January 9, 2020. https:\/\/cfirguide.org\/"},{"key":"bibr55-08897077231191840","doi-asserted-by":"publisher","DOI":"10.1186\/1748-5908-4-38"},{"key":"bibr56-08897077231191840","doi-asserted-by":"publisher","DOI":"10.1177\/0539018406069584"},{"key":"bibr57-08897077231191840","doi-asserted-by":"publisher","DOI":"10.1177\/1525822X05279903"}],"container-title":["Substance Abuse"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08897077231191840","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/08897077231191840","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08897077231191840","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T20:40:22Z","timestamp":1777668022000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/08897077231191840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["10.1177\/08897077231191840"],"URL":"https:\/\/doi.org\/10.1177\/08897077231191840","relation":{},"ISSN":["0889-7077","1547-0164"],"issn-type":[{"value":"0889-7077","type":"print"},{"value":"1547-0164","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7]]}}}